To read this content please select one of the options below:

Overview

Pharmaceutical Markets and Insurance Worldwide

ISBN: 978-1-84950-716-5, eISBN: 978-1-84950-717-2

Publication date: 25 March 2010

Abstract

Pedro Pita Barros reviews pharmaceutical policies adopted by health care systems in European (OECD) countries. He notes that cost-sharing for pharmaceuticals is higher than cost-sharing for other services. However, although pharmaceutical cost-sharing is pervasive across the European Union, concerns over equity have led most countries to adopt sliding fee schedules and even outright exemptions from copayments for vulnerable populations such as the elderly and low income households. The most common form of price regulation in these countries is reference pricing, either “external” (pegging pharmaceutical payments to lowest prices in a group of countries) or “internal” (pegging pharmaceutical prices to the lowest price within a therapeutic class), as well as outright administrative price controls. In his theoretical results, Barros shows that reference pricing lowers cost to consumers the most, followed by administrative price lists, while the pure coinsurance system yields the higher total cost. To foster innovation, Barros proposes adoption of innovative payment schemes based on supply-side risk sharing whereby payments to drug manufacturers are tied to treatment results and patient outcomes. Such schemes are akin to pay-for performance methods used to reimburse physicians in certain managed care settings in the United States.

Citation

Dor, A. (2010), "Overview", Dor, A. (Ed.) Pharmaceutical Markets and Insurance Worldwide (Advances in Health Economics and Health Services Research, Vol. 22), Emerald Group Publishing Limited, Leeds, pp. xiii-xxi. https://doi.org/10.1108/S0731-2199(2010)0000022003

Publisher

:

Emerald Group Publishing Limited

Copyright © 2010, Emerald Group Publishing Limited